Astellas Pharma Inc (ALPMY)

$16.20 +0.46 (2.92%)
Market Cap 28.48B
Revenue (ttm) 12.62B
Net Income (ttm) 334.93M
EPS (ttm) N/A
PE Ratio 10.99
Forward PE 24.41
Profit Margin 2.65%
Debt to Equity Ratio 0.46
Volume 224,100
Avg Vol 119,790
Day's Range N/A - N/A
Shares Out 1.81B
Stochastic %K 85%
Beta 0.18
Analysts Sell
Price Target $16.70

Company Profile

Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy secondary to age-related macular degeneration;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 81 3 3244 3000
Address:
2-5-1, Nihonbashi-Honcho, Chuo, Japan
Quantumup
Quantumup May. 28 at 11:11 AM
Barclays🏁 $STRO and said: We initiate coverage of Sutro Bio (STRO) at Overweight with a $56 price target. $PFE GMAB $ALPMY MRSN MGNX IDYA ABBV Here's what else Barclays had to say in its initiation report: https://x.com/Quantumup1/status/2059954928584462482?s=20
0 · Reply
Quantumup
Quantumup May. 22 at 3:16 PM
Truist⬆️the PT on $ABCL to $12 (was $10), reiterated at Buy and said—Clinical Signal & Platform Promise: What VMS Data Could Mean for ABCL's Next Phase $ALPMY $BAYRY Truist added—We reiterate our ABCL Buy rating following Ph1 ABCL-635 data that shows 1) target engagement and 2) clean safety profile that could support a superior safety profile vs. competitors. We look to Ph2 data (3Q26) to confirm or exceed efficacy seen with Veozah/Lynkuet and see favorable risk-reward benefit leading into the data. We believe 635 showing pbo-adjusted reductions in VMS frequency of ~20-25% and severity of ~10-15% could lead to upside potential of 20-60%+ vs. 20-40% downside from negative data (preview w/ scenario analyses). We updated our model to include a VMS revenue build (vs. prior project fee), reflecting how we think investors will view the stock.
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 May. 19 at 10:05 PM
$ABBV $ALPMY $NVS $SLS Trading will be halted before any Deal or Data PR! 🙏✌️❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 May. 19 at 8:47 PM
$SLS $ABBV $NVS $ALPMY These 4 companies drugs are going to be Obsolete after GPS FDA approval: AbbVie and Genentech: Venclexta (venetoclax) Astellas Pharma: Xospata (gilteritinib) Novartis Pharmaceuticals: Rydapt (midostaurin) Bristol Myers Squibb: Onureg Combined Sellas Platform can treat entire AML from start to finish and will make $10 Billion dollar blockbusters Obsolete. ABBV and Merck will be the biggest looser of the imminent bidding war if they don’t make a move pre- GPS Regal Pivotal Registrational Phase 3 study. SLS GPS will dethrone Merck’s Keytruda as # 1 selling drug on the planet with peek sales of $35 Billion + Mark this post and frame it, Bidding war= $280.00+ 🙏✌️❤️‍🩹
0 · Reply
Quantumup
Quantumup May. 12 at 12:43 PM
Stifel y'day⬆️ $ABCL's PT to $8 (was $7), reit'd Buy/said it now models ABCL635 peak U.S. sales of $1.4B and $800M in menopause-related VMS and oncology-related (specifically early-stage breast cancer) VMS. $ALPMY $BAYRY Here's what Stifel said in its note: https://x.com/Quantumup1/status/2054180048857424221?s=20
0 · Reply
Quantumup
Quantumup Mar. 19 at 3:54 PM
Cantor reiterated $ANNX Overweight ISEE - $ALPMY BofA reit'd Buy; $8 after ANNX's Geographic Atrophy Investor Day where BofA said: Vonaprument's novel MoA could drive visual acuity benefit Here's what Cantor and BofA had to say: https://x.com/Quantumup1/status/2034658656029954490?s=20
1 · Reply
LibertarianTreehugger
LibertarianTreehugger Feb. 24 at 9:45 PM
Vir Biotechnology (NASDAQ: VIR) Soars 27.7% on Big Pharma Deal: https://www.smartinvestornews.com/all-articles/vir-biotechnology-nasdaq-vir-soars-27-7-on-big-pharma-deal $VIR $ALPMY
0 · Reply
briefingcom
briefingcom Feb. 24 at 1:28 PM
$VIR: Vir Biotechnology (+34.5%) surging on earnings and updated Phase 1 trial results for PSMA-targeting, PRO-XTEN dual-masked T-cell engager VIR-5500. Also strategic collaboration with Astelas Pharma $ALPMY; and upgraded to Strong Buy from Outperform at Raymond James.
0 · Reply
dubliner1967
dubliner1967 Jan. 14 at 3:53 AM
$ALPMY Spoke at JPMorgan Pharma Conference... Possible Ironwood Acquiror.. Linzess Partnership? Article here.. https://theabominablesnowman.substack.com/p/ironwood-pharma-cheap-4x-pe-and-for
0 · Reply
CheesyBurrito
CheesyBurrito Jan. 12 at 4:59 PM
$SGMO $SGMO $ALPMY The Astellas presentation at JPM Healthcare conference is at 3p PT today. Hopefully we at least get some strong hints that tilt us toward Astellas, or perhaps Takeda. Supposedly, a copy of the presentation materials and webcast link will be posted on the http://Astellas.com investor relations page later today, but I haven’t seen anything yet. Very interesting that they’re doing a webcast!
0 · Reply
Latest News on ALPMY
No data available.
Quantumup
Quantumup May. 28 at 11:11 AM
Barclays🏁 $STRO and said: We initiate coverage of Sutro Bio (STRO) at Overweight with a $56 price target. $PFE GMAB $ALPMY MRSN MGNX IDYA ABBV Here's what else Barclays had to say in its initiation report: https://x.com/Quantumup1/status/2059954928584462482?s=20
0 · Reply
Quantumup
Quantumup May. 22 at 3:16 PM
Truist⬆️the PT on $ABCL to $12 (was $10), reiterated at Buy and said—Clinical Signal & Platform Promise: What VMS Data Could Mean for ABCL's Next Phase $ALPMY $BAYRY Truist added—We reiterate our ABCL Buy rating following Ph1 ABCL-635 data that shows 1) target engagement and 2) clean safety profile that could support a superior safety profile vs. competitors. We look to Ph2 data (3Q26) to confirm or exceed efficacy seen with Veozah/Lynkuet and see favorable risk-reward benefit leading into the data. We believe 635 showing pbo-adjusted reductions in VMS frequency of ~20-25% and severity of ~10-15% could lead to upside potential of 20-60%+ vs. 20-40% downside from negative data (preview w/ scenario analyses). We updated our model to include a VMS revenue build (vs. prior project fee), reflecting how we think investors will view the stock.
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 May. 19 at 10:05 PM
$ABBV $ALPMY $NVS $SLS Trading will be halted before any Deal or Data PR! 🙏✌️❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 May. 19 at 8:47 PM
$SLS $ABBV $NVS $ALPMY These 4 companies drugs are going to be Obsolete after GPS FDA approval: AbbVie and Genentech: Venclexta (venetoclax) Astellas Pharma: Xospata (gilteritinib) Novartis Pharmaceuticals: Rydapt (midostaurin) Bristol Myers Squibb: Onureg Combined Sellas Platform can treat entire AML from start to finish and will make $10 Billion dollar blockbusters Obsolete. ABBV and Merck will be the biggest looser of the imminent bidding war if they don’t make a move pre- GPS Regal Pivotal Registrational Phase 3 study. SLS GPS will dethrone Merck’s Keytruda as # 1 selling drug on the planet with peek sales of $35 Billion + Mark this post and frame it, Bidding war= $280.00+ 🙏✌️❤️‍🩹
0 · Reply
Quantumup
Quantumup May. 12 at 12:43 PM
Stifel y'day⬆️ $ABCL's PT to $8 (was $7), reit'd Buy/said it now models ABCL635 peak U.S. sales of $1.4B and $800M in menopause-related VMS and oncology-related (specifically early-stage breast cancer) VMS. $ALPMY $BAYRY Here's what Stifel said in its note: https://x.com/Quantumup1/status/2054180048857424221?s=20
0 · Reply
Quantumup
Quantumup Mar. 19 at 3:54 PM
Cantor reiterated $ANNX Overweight ISEE - $ALPMY BofA reit'd Buy; $8 after ANNX's Geographic Atrophy Investor Day where BofA said: Vonaprument's novel MoA could drive visual acuity benefit Here's what Cantor and BofA had to say: https://x.com/Quantumup1/status/2034658656029954490?s=20
1 · Reply
LibertarianTreehugger
LibertarianTreehugger Feb. 24 at 9:45 PM
Vir Biotechnology (NASDAQ: VIR) Soars 27.7% on Big Pharma Deal: https://www.smartinvestornews.com/all-articles/vir-biotechnology-nasdaq-vir-soars-27-7-on-big-pharma-deal $VIR $ALPMY
0 · Reply
briefingcom
briefingcom Feb. 24 at 1:28 PM
$VIR: Vir Biotechnology (+34.5%) surging on earnings and updated Phase 1 trial results for PSMA-targeting, PRO-XTEN dual-masked T-cell engager VIR-5500. Also strategic collaboration with Astelas Pharma $ALPMY; and upgraded to Strong Buy from Outperform at Raymond James.
0 · Reply
dubliner1967
dubliner1967 Jan. 14 at 3:53 AM
$ALPMY Spoke at JPMorgan Pharma Conference... Possible Ironwood Acquiror.. Linzess Partnership? Article here.. https://theabominablesnowman.substack.com/p/ironwood-pharma-cheap-4x-pe-and-for
0 · Reply
CheesyBurrito
CheesyBurrito Jan. 12 at 4:59 PM
$SGMO $SGMO $ALPMY The Astellas presentation at JPM Healthcare conference is at 3p PT today. Hopefully we at least get some strong hints that tilt us toward Astellas, or perhaps Takeda. Supposedly, a copy of the presentation materials and webcast link will be posted on the http://Astellas.com investor relations page later today, but I haven’t seen anything yet. Very interesting that they’re doing a webcast!
0 · Reply
JKtech
JKtech Jan. 5 at 11:17 AM
ASCO GI 2026: What to watch The data is LIVE and Alpha Tau is the standout. Two massive abstracts prove Alpha DaRT is the next frontier in internal oncology: $DRTS - Abstract #1 shows breakthrough safety in advanced Pancreas cancer treatment. Ultra-high dose precision in "inoperable" tumors. Abstract #2 highlights immune markers-turning the tumor into its own vaccine. 31% insider skin-in-the-game + $12 analyst PT. $ACTU - Jan 9 Oral session on Elraglusib. Risk of death reduced by 37% in early looks. The market wants the full survival curves. $RNXT - Abstract #732. Proving their TAMP platform hits the tumor harder with fewer side effects than systemic chemo. $ALPMY - Late-breaking data on Zolbetuximab. Setting the "Precision" ceiling for the Gl sector
1 · Reply
Quantumup
Quantumup Dec. 17 at 1:45 PM
Citizens $TSHA Market Outperform/$8 $NGNE $NVS $ACAD AVXL $ALPMY Citizens said—Taysha (TSHA, MO, $8 PT) and Neurogene (NGNE, NC) are moving into registrational studies and both show significant promise. Both registrational studies are well-designed, according to Dr. Davies, to capture improvements in clinical benefit and leverage primary outcomes that are objective measurements of performance outcomes and not patient/caregiver reported or effort based, which are less meaningful.
1 · Reply
Quantumup
Quantumup Dec. 3 at 11:46 AM
William Blair🏁 $VRDN at an Outperform rating. $AMGN $NVS $ALPMY $RHHBY William Blair said, we are initiating coverage of Viridian with an Outperform rating and $47 fair value estimate, based on our belief that the company's anti-IGF-1R franchise represents a meaningful advance compared to Tepezza for the treatment of thyroid eye disease (TED). While we acknowledge that growth in the U.S. TED market has plateaued in recent years, we believe that new therapies offering a more convenient administration, cleaner picture of the adverse event profile of IGF-1R inhibition, and diplopia benefit in chronic disease have potential to grow the market. In particular, while we believe veligrotug has important advantages over Tepezza that could drive share capture and modest market expansion following a potential mid-2026 approval, we believe the bigger value driver is the subcutaneously administered VRDN-003, for which top-line Phase III data are expected in the first and second quarters of 2026.
0 · Reply
Quantumup
Quantumup Nov. 24 at 3:20 PM
Truist🏁 $VRDN Buy-$41 and said—We think VRDN is well-positioned following veligrotug's (Veli') BLA submission and potential launch in thyroid eye disease (TED). $AMGN $NVS $ALPMY $RHHBY Truist additionally said in its initiation report—Our valuation is driven by Veli', a full IGF-1R antagonist, which has shown differentiated efficacy — with markedly reduced treatment burden — in active and chronic TED, with support from KOLs, justifying our est. of a WW peak sales opportunity of ~$730M by 2031. We also see the layering of a larger opportunity for VRDN-003, a half-life extended subcutaneous (SC) formulation, which we est. could command a WW peak sales opportunity of $1.5B in 2034. An early autoimmune pipeline diversifies the opportunity.
0 · Reply
Quantumup
Quantumup Oct. 20 at 8:30 PM
Raymond James🏁 $TSHA Strong Buy/$13 $NGNE $ACAD $ALPMY Raymond James said: Initiating coverage of Taysha Gene Therapies (TSHA) with a Strong Buy rating and $13 price target, as we think TSHA is well-positioned for success in its pivotal trial for patients with Rett syndrome (RTT), based on strong results from Part A of the Phase 1/2 REVEAL trial and constructive feedback from FDA. Raymond James added:
0 · Reply
Quantumup
Quantumup Oct. 13 at 3:36 PM
Citizens reiterated $TSHA Market Outperform-$6 and said, We continue to highlight TSHA as an opportunity based on the efficacy in Rett, clean safety (non-systemic) and regulatory clarity. $NGNE $ACAD $ALPMY Citizens JMP added: A key consideration for investors interested in TSHA has been comparison to NGNE, the most relevant Rett gene therapy competitor. We continue to see distinct differences between the Rett clinical strategies of TSHA and NGNE and supportive data: Overall, both TSHA & NGNE maintain that their asset has better biodistribution with their chosen administration route— intrathecal lumbar (IT-L) for TSHA and intracerebrovascular (ICV) for NGNE. Based on the more involved procedure required for ICV administration, we think TSHA has a slight edge on route of administration. In terms of comparison on biodistribution, we think that the clinical data can speak for itself here; both assets appear to deliver gene therapy to the critical brain structures imparting a clinical effect.
0 · Reply
Quantumup
Quantumup Sep. 12 at 11:47 AM
Citizens reiterated $TSHA Market Outperform-$6 and said, Taysha Gene Therapies is developing TSHA-102 for Rett Syndrome with remarkable impact on developmental milestones. $ALPMY Citizens added:
0 · Reply
Quantumup
Quantumup Aug. 1 at 1:06 PM
Cantor⬆️ $APLS PT to $40 from $39, reiterated at an Overweight and said it thinks Empaveli C3G launch will go well. $NVS AZN $ALPMY $OCUL $EYPT REGN SRZN RHHBY Cantor said in its note: "We reiterate Overweight rating on $APLS as GA market is stabilizing and the launch in C3G/IC-MPGN is under way. C3G patients and nephrologists face a decision on how to treat their C3 glomerulopathy diagnosis: by inhibiting C3 (with Empaveli) .... or by inhibiting "FaCtOr B" (woozy emoji). Never mind in addition to actually reducing C3 deposits, Empaveli also has meaningfully better efficacy, a broader label, and absence of a hyperlipidemia warning found in Fabhalta's label. Consequently, we think Empaveli C3G launch will go well."
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Jul. 14 at 8:26 PM
$TNXP $REPL $GSK $ALPMY
0 · Reply
globalHCanalyticsLLC
globalHCanalyticsLLC Jul. 14 at 7:27 PM
$TNXP brother the 52 week high is $130 from when the FDA decided we don’t need an advisory panel. $44.85 is not the ceiling. We’re buying at a third of the ceiling and once approved this should be smashing that $130 level. Trying not to spam the board but this has much more upside than $REPL or $GSK or $ALPMY with their PDUFAs looming in July 🚀
1 · Reply
Quantumup
Quantumup Jul. 10 at 7:51 PM
Cantor reiterated $APLS Overweight/$39 after competitor $ALPMY reported preliminary IZERVAY™ figures. $OCUL $EYPT REGN $SRZN RHHBY William Blair reiterated $APLS at an Outperform rating after competitor $ALPMY hosted a business update call to provide a U.S. commercial update on Izervay. Both Seem to Question #s Cantor and William Blair said in their notes to investors:
2 · Reply
Quantumup
Quantumup Jul. 8 at 12:26 PM
Ladenburg Thalmann🏁 $ORIC Buy-$15. $PFE $ALPMY $AMGN $TNGX Ladenburg Thalmann said in its research report: "Initiating coverage of $ORIC with a Buy rating and $15 price target based on 1) emerging profile of the PRC2 inhibitor ORIC-944 as a potential fast-follower to mevrometostat in treatment AR-experienced mCRPC, 2) strategic pivot for development of ORIC-114 from 2nd-line exon 20 EGFR/HER2 tumors to the 1st-line representing a larger addressable population and opportunity to maximize clinical differentiation based on potential best-in-class CNS activity and 3) experienced management team with a track record of guiding targeted cancer drugs through clinical development."
0 · Reply